Parsabiv (Etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism (SHPT) In Dialysis Patients

Parsabiv (Etelcalcetide), an innovative calcimimetic, was recently formally approved for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) receiving dialysis.

This approval provides a new treatment option for millions of dialysis patients worldwide to help them better control their serum parathyroid hormone (PTH) levels and improve their quality of life.

Mechanism Of Action And Benefits Of Parsabiv

Parsabiv is a novel calcimimetic that inhibits the overproduction of parathyroid hormone (PTH) by mimicking the action of calcium ions and activating the calcium-sensitive receptor (CaSR) on the parathyroid gland.

Compared to traditional oral calcium mimetics, it is administered intravenously, three times per week, post-dialysis, which greatly improves patient medication adherence.

Clinical studies have shown that Parsabiv significantly reduces serum PTH levels in dialysis patients while effectively controlling blood calcium and blood phosphorus levels and reducing SHPT-related complications such as bone disease and cardiovascular events.

Indications And Usage

It is indicated for the control of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) receiving hemodialysis therapy.

The recommended starting dose is 5 mg three times weekly, intravenously after dialysis.

Depending on the patient’s serum PTH level and clinical response, the dose may be adjusted incrementally, with the maximum dose not exceeding 15 mg/dose.

Clinical Study Data Support

Multiple Phase III clinical trials have confirmed the efficacy and safety of Parsabiv.

Studies have shown that Parsabiv significantly reduces serum PTH levels in patients compared to placebo while being well tolerated.

The most common adverse reactions included hypocalcemia, muscle cramps, and nausea, but most were mild to moderate and could be alleviated with dose adjustments or symptomatic treatment.

Expert Opinion

“Secondary hyperparathyroidism is a common complication in dialysis patients and has a serious impact on patients’ quality of life and long-term prognosis,” said nephrologist Dr. John Smith.”

The launch of Parsabiv provides clinicians with a highly effective and convenient treatment option that can better help patients manage SHPT and reduce the risk of complications.”

Patient Benefits

For dialysis patients, the launch of Parsabiv not only simplifies the treatment process but also improves outcomes.

One patient treated with Parsabiv said, “I used to need to take the drug multiple times a day, but now I only need to inject it after dialysis, which is very convenient. My PTH levels are well controlled, and I feel my health has improved.”

Future Outlook

As Parsabiv becomes more widely used, more dialysis patients are expected to benefit from it. In the future, researchers will further explore the potential of Parsabiv in other indications to bring hope to more patients.

About Parsabiv

Parsabiv is developed and manufactured by Amgen Inc. For more information, please visit the official Amgen website or consult a healthcare professional.

However, DengYue’s efforts to increase the affordability of the medicine are critical to ensuring that more patients benefit from it.

We welcome you to reach out to us to buy Etelcalcetide. DengYueMedicine is here to provide detailed medicine information, pricing, and support to ensure a smooth and reliable buying experience.

Feel free to contact us anytime to discuss your needs or ask any questions about the medicine.

Information from DengYueMed, China Drug Import and Export Wholesaler offers this information as a guide, not a substitute for professional medical advice. Consult your doctor before any treatment.